International Conference and Expo on

Clinical Microbiology

June 17-18, 2022 | Online Event

ICCM 2022

Utilization of SARS CoV 2 serology in Public Health and Clinical Uses

Speaker at Clinical Microbiology 2022 - Muhammad Morshed
University of British Columbia, Canada
Title : Utilization of SARS CoV 2 serology in Public Health and Clinical Uses


The SARS-CoV-2 virus causes COVID-19 disease, which was first diagnosed in late December 2019 among a few people with unknown respiratory illness in Wuhan city, Hubei province, China.  Presumably this virus jumped from a natural host to human, and that occurred in one of the open food markets in Wuhan city, spreading very quickly to neighbouring provinces, neighbouring countries and eventually different continents. The World Health Organization declared the outbreak a Public Health Emergency of International Concern on 30 January 2020, and a pandemic on 11 March 2020. This virus killed over 5.5 million people globally as of 2021 and there is no sign of stopping with the latest addition of Omicron variant. However; SARS CoV-2 also forced us to invent new skills and technology not only to defeat it but also to propel ourselves forward. For instance, serological diagnostic tests in the form of Point of Care Test (POCT) format and regular EIA format become available in a couple of months instead of years.
Although molecular/ RT PCR become the test of choice for clinical diagnosis, serology has also limited uses for patient care in addition to Public Health (PH) uses. For PH, SARS-CoV-2 antibody testing is testing is essential for estimating population based seroprevalence and also to assess vaccine efficacy or responses which enable evidence-based decision making for public health recommendations. For clinical care, SARS CoV-2 antibody testing help select group of population where molecular/PCR test is negative. So it may help to increase case identification when used as an adjunct to routine molecular testing in those select cohorts; however, it is become challenging due to the emergence of new variants. So, in this presentation we will review serological testing of patients’ blood against SARS Cov-2 virus and highlight pros and cons of uses of serological testing in public health and its uses of clinical diagnosis.


Dr Morshed received his PhD from the Yamaguchi University School of Medicine (Japan) in 1994. He completed his specialty training at the Research Institute of Tuberculosis in Tokyo and at the College of Natural Resources, University of California (Berkeley). 
Dr. Morshed is recognized by the national and international research community for his expertise on spirochaetal diseases. He is a member of many provincial, national and international working groups and networks in the area of zoonotic and emerging pathogens and serves on the executive boards of the Canadian College of Microbiologists (CCM) and Canadian Association for Clinical Microbiology and Infectious Diseases (CACMID). He received an Excellence in Clinical Services Award from the UBC Department of Pathology & Laboratory Medicine in 2016, was named a winner in the RBC Top 25 Canadian Immigrant Awards in 2017, received the Distinguished Microbiologist Award from the Canadian College of Microbiologists (CCM) in 2019 and became elected as an Expatriate Fellow by the Bangladesh Academy of Sciences (BAS) in 2020.